Suppr超能文献

羟钴胺素治疗肺移植术后血管麻痹:病例系列

Hydroxocobalamin for the treatment of vasoplegia after lung transplantation: A case series.

作者信息

Nguyen Anh, Bouajram Rima, Brzezinski Marek, Hassanipour Sahand, Gordon David, Trinh Binh, Deuse Tobias, Venado Aida, Hays Steve, Singer Jonathan, Kukreja Jasleen

机构信息

Baylor College of Medicine, Houston, Texas.

University of California San Francisco, San Francisco, California.

出版信息

JHLT Open. 2024 Nov 29;7:100189. doi: 10.1016/j.jhlto.2024.100189. eCollection 2025 Feb.

Abstract

BACKGROUND

The use of hydroxocobalamin following lung transplantation has not been previously reported. We present a series of 3 cases where hydroxocobalamin was used to treat postoperative vasoplegia.

METHODS

We conducted a single-center, retrospective review of lung transplantation recipients from January 2016 to December 2020. We used cumulative vasopressor index to standardize vasopressor dose administered and mean arterial pressure at 2- and 24-hour time-points following hydroxocobalamin administration to assess treatment effectiveness.

RESULTS

We identified 3 male patients aged 49 to 62, with lung allocation scores between 89.9 and 90.6, requiring extracorporeal membrane oxygenation support (pre- and post-transplant for 5, 5, 9 and 8, 2, 2 days, respectively). Each patient received hydroxocobalamin 5,000 mg infused over 15 minutes, with patient #3 receiving an additional 6 doses over the subsequent 4 days. At the 2-hour time-point, mean arterial pressure increased in all patients (+11%, +17%, and +13%, respectively), although cumulative vasopressor indexes were inconsistent. At 24 hours, patients #1 and #2 demonstrated a marked increase in mean arterial pressure (36% and 23%, respectively) and a decrease in cumulative vasopressor index, while patient #3 displayed stable with slight reduction in cumulative vasopressor index and mean arterial pressure values. No allergic reactions were observed. Patient #3 developed methemoglobinemia and a medication-related false increase in triglycerides. All 3 patients were discharged home.

CONCLUSIONS

Hydroxocobalamin may be a valuable adjunct in managing refractory vasoplegia following lung transplantation.

摘要

背景

此前尚无肺移植后使用羟钴胺素的报道。我们报告了3例使用羟钴胺素治疗术后血管麻痹的病例。

方法

我们对2016年1月至2020年12月期间的肺移植受者进行了单中心回顾性研究。我们使用累积血管升压药指数来标准化血管升压药的给药剂量,并在给予羟钴胺素后的2小时和24小时时间点测量平均动脉压,以评估治疗效果。

结果

我们确定了3名年龄在49至62岁之间的男性患者,肺分配评分在89.9至90.6之间,均需要体外膜肺氧合支持(移植前和移植后分别为5天、5天、9天和8天、2天、2天)。每名患者均在15分钟内输注了5000毫克羟钴胺素,患者3在随后4天内又额外接受了6次给药。在2小时时间点,所有患者的平均动脉压均升高(分别升高11%、17%和13%),尽管累积血管升压药指数并不一致。在24小时时,患者1和患者2的平均动脉压显著升高(分别为36%和23%),累积血管升压药指数降低,而患者3的情况稳定,累积血管升压药指数和平均动脉压值略有下降。未观察到过敏反应。患者3出现了高铁血红蛋白血症和与药物相关的甘油三酯假性升高。所有3名患者均出院回家。

结论

羟钴胺素可能是治疗肺移植后难治性血管麻痹的一种有价值的辅助药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc54/11935413/e00ab4254e76/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验